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Pregnancy of unknown location is a situation in which a positive pregnancy test occurs, but a transvaginal
ultrasound does not show intrauterine or ectopic gestation. One great concern of pregnancy of unknown loca-
tion is that they are cases of ectopic pregnancy whose diagnosis might be postponed. Transvaginal ultrasound is
able to identify an ectopic pregnancy with a sensitivity ranging from 87% to 94% and a specificity ranging from
94% to 99%. A patient with pregnancy of unknown location should be followed up until an outcome is
obtained. The only valid biomarkers with clinical application and validation are serum levels of the beta fraction
of hCG and progesterone. A single serum dosage of hCG is used only to determine whether the value obtained
is above or below the discriminatory zone, that means the value of serum hCG above which an intrauterine
gestational sac should be visible on ultrasound. Serum progesterone levels are a satisfactory marker of
pregnancy viability, but they are unable to predict the location of a pregnancy of unknown location: levels
below 5 ng/mL are associated with nonviable gestations, whereas levels above 20 ng/mL are correlated with
viable intrauterine pregnancies. Most cases are low risk and can be monitored by expectant management with
transvaginal ultrasound and serial serum hCG levels, in addition to the serum progesterone levels. To minimize
diagnostic error and intervene during progressive intrauterine gestation, protocol indicates active treatment
only in situations when progressive intrauterine pregnancy is excluded and a high possibility of ectopic
pregnancy exists.
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’ PREGNANCY OF UNKNOWN LOCATION:
CLASSIFICATION AND FOLLOW-UP
Pregnancy of Unknown Location (PUL) is the term used
to describe a situation in which a positive pregnancy test
occurs, but a transvaginal ultrasound (TVUS) does not show
intrauterine or ectopic gestation, nor does it show the reten-
tion of conception products (1). The incidence of PUL at
centers specialized in the follow-up of early gestation varies
from 8% to 10% (2,3) and fundamentally depends on the
quality of the ultrasound examination performed, which in
turn results from the examiner’s experience and the degree of
resolution of the device used. The International Consensus of
Ultrasound in Obstetrics and Gynecology determined that
units specialized in early gestation should strive to maintain
a PUL rate below 15% (4).
Ultrasonography is the best examination method for iden-
tifying the location of an early pregnancy. One study con-
ducted in London at a unit specialized in early gestation
showed that TVUS identified the location of the pregnancy
in 91.3% of pregnant women. Of these women, 89.6% were
diagnosed with intrauterine pregnancies (IUPs), 1.7%
were diagnosed with ectopic pregnancies (EPs), and 8.7%
were diagnosed with PUL (5). One great concern of PULs is
that they are cases of ectopic pregnancy whose diagnosis
might be postponed. TVUS is able to identify an EP with a
sensitivity ranging from 87% to 94% and a specificity ranging
from 94% to 99% when multiple exams are performed. With
a single examination, TVUS identifies EPs with 73.9% sensiti-
vity and 98.3% specificity (6). Regarding PULs, a common
mistake is to perform TVUS alone. The adnexa might be
located in a higher region, and only a pelvic abdominal ultra-
sound enables visualization and identification via a sugges-
tive image to diagnose EP (7).
PUL rates and outcomes vary widely because of the
different criteria used by several centers worldwide. Thus,
experts from the United Kingdom, the United States, Belgium,
the Netherlands, and Australia reached a consensus to stan-
dardize the ultrasound criteria for IUPs and EPs in 2011 (8).
Faced with a positive pregnancy test, a woman can be classi-
fied into one of five categories based on her ultrasound
findings:
1. Defined EP: extrauterine gestational sac with a yolk
vesicle and/or embryo with or without cardiac activity
2. Probable EP: heterogeneous adnexal mass or gestational
sac-like structure
3. PUL: absence of IUP or EP imagesDOI: 10.6061/clinics/2019/e1111
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4. Probable IUP: presence of intrauterine echogenic gesta-
tional sac
5. Defined IUP: intrauterine gestational sac with yolk vesicle
and/or embryo with or without cardiac activity
’ CLASSIFICATION
A patient with PUL should be followed up until an out-
come is obtained. The follow-up of a patient with PUL can
result in four possibilities (8):
1. IUP: In this case, the ultrasonographic examination is per-
formed early, and an intrauterine gestation is not identi-
fied. Where possible, the IUP is subdivided into viable
IUPs and nonviable IUPs. Between 30% and 47% of patients
with PUL are subsequently classified as IUP (1), where
 Viable IUP denotes ultrasound signs that are compa-
tible with gestational age
 IUP of uncertain viability denotes definite ultrasound
evidence of IUP; however, ultrasonographic signs are
insufficient to indicate whether the gestation is viable
 Nonviable IUP: ultrasound signs show anembryo-
nic gestation, miscarriage, or the retention of the pro-
ducts of conception
2. Failed PUL (PULF): In this case, the spontaneous outcome
of gestation occurs with negative human chorionic
gonadotropin (hCG), but the exact location of gestation
(i.e., whether intrauterine or ectopic) is never identified.
Between 50% and 70% of PULs are classified as PULF.
Thus, IUP and PULF represent forms of PUL considered
low risk for complication (1)
3. EP: PUL should not be considered a synonym of EP or as
EP until proven otherwise. Between 6% and 20% of PULs
are classified as EPs (1)
4. Persistent PUL (PULP): Approximately 2% of patients
with PUL are classified as PULP (9). In these cases, hCG
does not decline spontaneously, an abnormal increase or
plateau of hCG occurs (a variation of less than 15% in
hCG titration over three consecutive 48-hour interval
measurements), and TVUS does not show intrauterine or
ectopic gestation. These cases are usually small EPs that
are not visualized on ultrasound or represent the retention
of the products of conception in the endometrial cavity
with an active trophoblast. Cases of EP and PULP are
considered high risk for complication (1). PULP is not a
diagnosis, and its outcome depends on the following
conduct (8):
 EP not visualized: In this case, an increase in hCG
titers occurs after uterine evacuation
 Treated PULP: In this case, methotrexate (MTX) is
administered without confirmation of the location
of pregnancy via ultrasonography, laparoscopy, or
uterine evacuation
 Resolved PULP: This type is present when hCG titers
are negative after expectant management or uterine
evacuation, without evidence of chorionic villi on
anatomopathological examination
 Histological IUP: In this case, chorion villus is
identified on anatomopathological examination after
uterine evacuation
’ FOLLOW-UP
PUL is not a diagnosis, and the patient should be followed
up until a definitive diagnosis is made. Although consensus
exists regarding the definitions and classification of PUL (8),
unfortunately, globally accepted protocols are lacking for
PUL follow-up assessments, which leads to stress and addi-
tional tests until an outcome is established. In a PUL follow-
up, biomarkers are useful because they can help determine
the location and viability of gestation. An ideal biomarker
should be inexpensive, accurate, reproducible, and safe.
Biomarkers can be classified into subgroups that reflect the
function of the trophoblast, corpus luteum, endometrium,
and angiogenesis (10). Most biomarkers are in the research
phase and have not been tested in clinical trials. The only
valid biomarkers with clinical application and validation are
serum levels of the beta fraction of hCG and progesterone.
’ HCG
hCG is the most widely used biomarker in PUL follow-
ups. A single serum dosage of hCG cannot be used to predict
the outcome of a PUL; rather, it is used only to determine
whether the value obtained is above or below the discrimi-
natory zone. The discriminatory zone or a discriminatory
value indicates the value of serum hCG above which an
intrauterine gestational sac should be visible on ultrasound
(11). This value varies across various centers and fundamen-
tally depends on the resolution degree of the ultrasound
device, the examiner’s experience, and the hCG kit used by
the laboratory. Currently, most services consider a discrimi-
natory zone between 1,500 and 2,000/2,500 mIU/mL of hCG
while using TVUS (12,13). When the hCG value is above the
discriminatory zone and no intrauterine gestation is visible
on TVUS, an EP should be suspected; however, it is possible
to have a viable IUP even if the ultrasound does not show an
IUP, and the hCG value is above the discriminatory zone.
Several studies have documented the appearance of embryos
with cardiac activity in the follow-up of pregnancies where
the gestational sac was not visible on TVUS with hCG values
above 2,000 mIU/mL (14-16). One study used a logistic
regression model to calculate the probability of visualizing a
gestational sac on TVUS by evaluating 651 pregnant women
with vaginal bleeding and/or abdominal pain; of these cases,
366 were viable pregnancies. To obtain a 99% probability of
visualizing an intrauterine gestational sac on TVUS, the
discriminatory value of hCG should reach 3,510 mIU/mL. If
hCG values of 1,500 and 2,000 mIU/mL are used, then the
probabilities of visualizing a gestational sac are 80.4% and
91.2%, respectively (15). Other reasons for nonvisible ges-
tational sacs with hCG values above the discriminatory zone
are multiple gestation, the examiner’s experience, ultra-
sound resolution, obesity, uterine fibroids, uterine polyp, and
the hCG standardization used by the laboratory (7,14,16).
To avoid the risk of a diagnostic error that might lead to
the interruption of a viable pregnancy or a malformation due
to MTX use (17,18), interventional conduct should not be
instituted based on a single dose of hCG among patients
with PUL who are hemodynamically stable. For a woman
with PUL and hCG values above 2,000 mIU/mL, the most
likely diagnosis is a nonviable IUP, which is twice as frequent
as EP (14,19). On the other hand, EPs occur 19 times more
frequently than viable IUPs if hCG titers are between 2,000
and 3,000 mIU/mL and are 70 times more frequent than
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viable IUPs if hCG titers are above 3,000 mIU/mL (14,20).
Among PULs with hCG values between 2,000 and 3,000
mIU/mL, each viable IUP will be accompanied by 19 EPs
and 38 nonviable IUPs. Therefore, the probability of a viable
IUP in this situation is 1C(1+19+38), which is approxi-
mately 2%. Likewise, if the hCG value is greater than 3,000
mIU/mL, each viable IUP will be accompanied by 70 EPs
and 140 nonviable IUPs. In this situation, the probability of a
viable IUP will be 1C(1+70+140), which is approximately
0.5% (21).
The most commonly used method for the follow-up of a
PUL is a serial serum hCG measurement. Kadar et al. (22)
were the first to describe that the minimum increase in serum
hCG in cases of progressive IUP over 48 hours was 66%.
However, this study was performed with only 20 patients
and a confidence interval (CI) of 85%. Subsequently, a study
of 287 patients who presented with vaginal bleeding, abdo-
minal pain, or both determined, with a 99% CI, that in 99% of
the progressive IUPs with hCG less than 5,000 mIU/mL, the
increase serum hCG over 48 hours was least 53% (23). More
recently, a study of 1,249 patients with PUL showed, with
a 99.9% CI, that the minimal increase in hCG in cases of
progressive IUP over 48 hours was 35% (24). The increase in
hCG at 48 hours in cases of progressive pregnancy differs
depending on the initial concentration of this hormone: it
increases 49% of the time when hCG is initially below 1,500
mIU/mL, 40% of the time when the initial hormone concen-
trations are between 1,500 and 3,000 mIU/mL, and 33% of
the time when initial hCG is higher than 3,000 mIU/mL (25).
Thus, a viable IUP can increase hCG more slowly than pre-
viously imagined and thereby decrease the risk of inadver-
tently interrupting a progressive gestation. The variation
between the serum titers of hCG at 48 hours/hCG at 0 hours
is called the hCG ratio, and it is the main method of follow-
up with a case of PUL. An increase greater than 66% in an
hCG titer at 48 hours (hCG ratio41.66) is highly suggestive
of a viable IUP (26). A decrease in hCG titers indicates a
nonprogressive gestation, and an hCG ratio of o0.87 (hCG
drop413%) suggests a PULF with a sensitivity of 92.7%
(95% CIs: 85.6%-96.5%) and a specificity of 96.7% (95% CIs:
90.0%-99.1%) (27). Conversely, if the hCG titers increase
by p66% (hCG ratiop1.66) or decrease by p13% (hCG
ratioX0.87), then the probabilities of EP and PULP increase (2).
Unfortunately, the pattern of variation in hCG titers over
48 hours cannot be used to diagnose the cases of PUL that
progress to EPs with certainty. In cases of LG, hCG titers can
increase, decrease, or stabilize. Most EPs exhibit a variation
in hCG titers within 48 hours, which increase more slowly
than viable IUPs or decrease more slowly than nonviable
IUPs. Approximately 15% to 20% of EPs can increase hCG
titers over 48 hours similar to a progressive IUP, whereas
10% of EPs show hCG behaviors at 48 hours similar to those
of PULF cases (28). The sensitivity of the hCG ratio (hCG at
48 hours/hCG at 0 hours) to predict an EP ranged from 74%
to 100%, and the specificity varied from 28% to 97% in a
meta-analysis that analyzed the accuracy of serum hCG at
the outcome of a PUL (29).
’ PROGESTERONE
Serum progesterone (P) is a natural progestogen produced
by the corpus luteum, placenta, and adrenal glands whose
primary function is to maintain pregnancy. Single serum
P doses have been used together with serum hCG doses in
the follow-up of PULs. Serum P levels are a satisfactory
marker of pregnancy viability, but they are unable to pre-
dict the location of a PUL. P levels below 5 ng/mL are
associated with nonviable gestations, whereas levels above
20 ng/mL are correlated with viable IUPs. However, a consi-
derable proportion of EPs present with P doses between
5 and 20 ng/mL, which limits its use in clinical practice to
exclude the possibility of EPs (12). Serum P doses are useful
in cases of PUL to identify patients with PULF and thereby
minimize the examinations and days of follow-up because
they are considered low risk, regardless of the location of the
pregnancy. A prospective study evaluating 252 cases of PUL
with Pp10 nmol/L found a positive predictive value for
PULF of 98.2% (95% CIs: 96.8%-99.7%) (3).
’ OTHER BIOMARKERS
Although only serum levels of hCG and P are used in
clinical practice, numerous biomarkers have been studied as
predictors of PUL such as creatine kinase, cancer antigen
125, inhibin A, inhibin pro-aC-related immunoreactivity, and
insulin-like growth factor-binding protein (30,31). To date,
only inhibin A doses have predicted PUL progression. Levels
of inhibin A are significantly lower in cases of PUL that
resolve spontaneously (i.e., PULF) compared with cases that
result in EPs and IUPs. A study of 109 women with PULs
demonstrated that all cases with titers of inhibin A p11
pmol/L resulted in PULF (31).
’ MATHEMATICAL MODELS
To improve care for women with PULs, polynomial
logistic regression models were developed to predict the
outcomes of PULs as well as minimize the exams and follow-
ups of patients classified as low or high risk. In this context,
the M4 (32-34) and M6 (35) models deserve mention. The M4
model was based on the hCG ratio (hCG at 48 hours/hCG at
0 hours) to calculate outcomes and classify patients. The
insertion of the hCG values in the M4 model calculates the
risks of PUL cases that result in EPs, IUPs, or PULF. This
model classifies PULs as low risk if the estimated rate of EP is
o5% and as high risk if the estimated rate of EP is X5%.
Follow-up of low-risk cases is performed with a urine hCG
test in 2 weeks (where the risk for a PULF is greater than the
risk for an IUP) or TVUS within 1 week (where the risk for an
IUP is greater than the risk for a PULF). For high-risk cases,
the serum levels of hCG are measured and TVUS is perfor-
med every 48 hours. A multicenter study of 1,962 women
with PUL showed that the M4 model identified 69.6% (95%
CIs: 65.8%-73.1%) of the patients as low-risk PULs with a
positive predictive value of 97.5% (95% CIs: 95.5%-98.6%).
The same study reported a sensitivity of 88% (95% CIs:
79.9%-93.2%) regarding the diagnosis of high-risk PUL cases
with outcomes of EPs or PULP (33). One study using this
same model in the US population did not show the same
accuracy, revealing a sensitivity of 49% in high-risk PUL
cases. The sensitivity increased slightly to 55% after adjusting
the diagnostic criteria of the American population to those
criteria used for the British population (36).
Recently, a new polynomial logistic regression model
called M6-P was developed, which involves two steps. Ini-
tially, a serum P dosage is performed. If the P titers are
p2 nmol/L, then the patient is considered low risk, and
the follow-up is performed via a urine hCG test in 2 weeks.
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In cases of P42 nmol/L, the patient receives a second test
that examines the hCG ratio (hCG at 48 hours/hCG at
0 hours). The M6-P model enables researchers to apply the
serum P-value to the formula; if the patient uses P supple-
mentation, then this test employs a variable to account for
this use. Similar to the M4 model, if the EP risk isX5%, then
the case is considered high risk, and the patient receives
serum doses of hCG and TVUS every 48 hours. On the other
hand, if the risk of EP iso5%, then a follow-up is performed
via a urine hCG test in 2 weeks (when the risk for a PULF is
greater than the risk for an IUP) or via TVUS within 1 week
(when the risk for an IUP is greater than the risk for a PULF).
The development of the M6-P model involved 2,753 cases of
PUL and showed that the initial stage identified 16.6% of the
cases as low risk, with only a single serum P-value; however,
2.9% of EPs were initially classified as low risk. With the
application of the two steps, the M6-P model can identify
62.1% of all cases as low risk, with a negative predictive
value of 98.6% and a sensitivity of 92%. A total of 7.9% of EPs
were initially classified as low risk PULs. The possibility of
erroneously classifying an EP as a low-risk PUL reinforces
the need to explain the signs of possible complications to
patients (35). The use of mathematical models to predict the
outcome of a PUL and minimize the number of follow-up
assessments and laboratory tests seems promising; however,
to clinically validate these mathematical models, it remains
necessary to test them in across multiple centers and diff-
erent populations. These mathematical models are available
at www.earlypregnancycare.com.
’ SURGERY
A lack of visualization of the intrauterine gestational sac
on TVUS, together with hCG values above the discrimina-
tory zone, was considered an indication for laparoscopy.
Currently, laparoscopy is reserved for cases of PUL with the
symptoms or signs of hemoperitoneum (1).
Uterine evacuation via curettage (D&C) or manual vacuum
aspiration (MVA) has been used primarily in the United States
to differentiate EP from nonviable cases of IUP. Those who
advocate for this conduct believe that the differentiation
between EPs and nonviable IUPs is important in the future
counseling of a new pregnancies because a history of EP
increases the risk of recurrence in the event of a future
gestation, and a nonviable IUP might be associated with
recurrent miscarriage requiring further investigation. Another
favorable point for uterine evacuation is that the unnecessary
use of MTX would be avoided in up to 50% of cases (37). The
presence of chorionic villi in the uterine evacuation material is
used to diagnose nonviable IUPs. Up to 20% of the time,
however, anatomopathological analyses do not show chor-
ionic villi (38). One should then perform serum hCG tests
immediately before uterine evacuation and 24 hours after-
wards. If hCG titers decrease by at least 15% after uterine
evacuation, then the diagnosis of a nonviable IUP will follow;
on the other hand, if the serum levels of hCG stabilize or
increase, then the most likely diagnosis will be EP, and the
patient will be treated with MTX because the possibility of
incomplete uterine evacuation is unlikely (39,40).
In cases of PUL, uterine evacuation should be an exception
and only performed after the possibility of a viable IUP has
been excluded. Unfortunately, the criteria commonly emp-
loyed to exclude the possibility that viable IUPs might
present a risk of viable gestation discontinuation (41).
’ MTX
MTX has been used in PULP cases of clinically stable
patients presumed to have EPs. Depending on patient
preferences, MTX can be offered as an alternative to uterine
evacuation. This drug is a chemotherapeutic agent antago-
nist of folic acid and shows a high success rate in selected EP
cases (12). A 50-mg/m2 dose of MTX is injected intramuscu-
larly, and if hCG does not decrease by at least 15% between
days 4 and 7, then the same dose of MTX is repeated (42).
Before initiating MTX treatment, it is essential that patients
present with normal complete blood count, urea, creatinine,
and liver enzyme tests. Side effects such as pneumonitis (43)
and febrile leukopenia (44,45) are extremely rare at typical
doses of MTX and have only been described as case reports
in the medical literature. As a consequence of the terato-
genic potential of this chemotherapeutic agent, the patient
should wait at least 3 months before trying to become
pregnant after MTX treatment (13,46). Like uterine evacua-
tion, before administering MTX, one must ensure that a
progressive IUP is not present. Unfortunately, diagnostic
errors have been described, which lead to congenital mal-
formations, abortions, and interruptions of desired pregnan-
cies (17,18).
A prospective, multicenter study randomly selected 73
hemodynamically stable patients diagnosed with EP with
hCG levels o1,500 mIU/mL or those diagnosed with PUL
with hCG levels o2,000 mIU/mL who presented with pla-
teau hCG levels (i.e., elevations or decreases in hCG titers
between the day of diagnosis and 4 days after o50%). A
total of 41 patients received MTX (1 mg/kg intramuscularly),
and 32 women were considered pregnant. Success was con-
sidered when hCG decreased until it reached undetectable
levels following the initial intervention. New interventions
were not necessary for 76% of the MTX group or 59% of the
expectant group (RR: 1.3, 95% CIs: 0.9-1.8). In the MTX
group, nine patients required a new dose of MTX (22%); in
the expectant group, MTX was administered to nine women
(28%; RR: 0.8, 95% CIs: 0.4-1.7). In that study, MTX was not
superior to expectant treatment in cases of EP or PUL with
low hCG titers or plateau hCG titers (47).
Recently, cases classified as PUL and initially treated with
MTX but who actually had hCG-producing tumors (i.e.,
gestational and nongestational choriocarcinomas) have been
described (48,49). Although rare, this possibility should be
kept in mind because the wrong diagnosis can postpone
appropriate treatment and create resistance to the che-
motherapeutic agent. Another possibility of diagnostic error
is the presence of heterophilic antibodies. Individuals with
heterophilic antibodies produce antibodies against antigens
of other species (e.g., mice). Currently, immunoassay enzy-
mes with mouse monoclonal antibodies are used in the
serum dosage of hCG. Thus, positive tests do not indicate
hCG production. This type of alteration has harmed several
women who, because of positive serum hCG levels, were
erroneously diagnosed with EP; in addition, those with hCG-
producing neoplasia underwent laparoscopy, hysterectomy,
or chemotherapy. Heterophilic antibodies are large molecules
that are not present in the urine, so one should consider
the possibility of heterophilic antibodies if the hCG test is
positive in the blood but negative in the urine. However,
urine serum levels can be negative because the small amount
of hCG produces a test with low sensitivity. In these cases,
it is necessary to use a heterophilic antibody blocker or to
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create diluted dosages of the sample for the correct diagnosis
of the heterophilic antibody (50,51).
Unfortunately, there is no consensus regarding the follow-
up and timing of any intervention in cases of PUL. Our
protocol is based on a discriminatory hCG value of 3,500
mIU/mL and variation in the hCG titers at 48 hours with
the measurement of serum progesterone (Figure 1). Patients
should be aware of the possibility of an EP and should
quickly seek care in the event of its signs and symptoms. We
choose expectant management for as long as possible, until
the hCG level reaches the discriminatory value of 3,500
mIU/mL, and the patient is asymptomatic or oligosympto-
matic. In the case of hCG titer plateau (i.e., variations of
o15% across three consecutive doses within a 48-hour
interval) with hCG values below 2,000 mIU/mL, we employ
expectant protocol. On the other hand, we opt for active
treatment when the plateau occurs with hCG titers 42,000
mIU/mL or hCG concentrations 43,500 mIU/mL, with an
elevation of at least 15% over 48 hours. Currently, when we
employ active treatment to avoid the unnecessary use of
MTX, we prefer to perform MVA on an outpatient basis
using local anesthesia via a paracervical block and aspiration
with a 4-mm cannula. The material obtained via uterine
evacuation is sent for anatomopathological study. If the hCG
concentration does not drop by at least 15% after uterine
evacuation, then the probable diagnosis will be EP, in which
case, we prescribe intramuscular MTX at a dose of 50 mg/
m2. In case of failure after the initial MTX cycle, we recom-
mend the chest, abdomen, and pelvis examinations via
computed tomography or magnetic resonance imaging to
exclude the possibility of a hCG-producing tumor before
starting a second cycle.
’ CONCLUSION
Women with PULs should be followed up until a final
diagnosis is established. In addition to TVUS, we routi-
nely recommend abdominal pelvic ultrasonography for the
complete visualization of the adnexa in cases of PUL.
Fortunately, most cases are low risk and can be monitored
by expectant management with TVUS and serial serum hCG
levels, in addition to the serum P levels. However, the
possibility of an EP, which has high morbidity and mortality
rates during the first trimester of pregnancy, remains. In our
view, one should have an active treatment to avoid delaying
the EP diagnosis in certain situations. To minimize diagno-
stic error and intervene during progressive intrauterine
gestation, our protocol indicates active treatment only in
situations when progressive IUP is excluded and a high
possibility of EP exists, i.e., when the hCG plateau is above
2,000 mIU/mL or the hCG concentration is above the
discriminatory value of 3,500 mIU/mL with hCG titer
elevation incompatible with progressive IUP.
Because consensus does not exist with regard to the
follow-up of patients with PULs, we believe that additional
studies are needed to elaborate algorithms to minimize
laboratory exams and patient follow-ups, thereby reducing
the costs and stress involved in the follow-up of these cases.
Before being universally employed, mathematical models
should be evaluated at several centers to ensure that they are
tested with regard to different populations.
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